These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29680267)

  • 21. Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects.
    Zhao L; Wang B; Wang L; Zhao X; Chen Z; Sun L
    Org Biomol Chem; 2019 Sep; 17(33):7760-7771. PubMed ID: 31389463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel peptidic dual GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound.
    Ding WX; Wang HY; Peng LJ; Zhang F; Yuan S; Zhao LH
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12423-12436. PubMed ID: 33336763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists.
    Zhang X; Cai Y; Yao Z; Chi H; Li Y; Shi J; Zhou Z; Sun L
    Peptides; 2023 Mar; 161():170948. PubMed ID: 36646385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats.
    Price SL; Minnion JS; Bloom SR
    Curr Ther Res Clin Exp; 2015 Dec; 77():111-5. PubMed ID: 26843896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents.
    Liu YL; Ford HE; Druce MR; Minnion JS; Field BC; Shillito JC; Baxter J; Murphy KG; Ghatei MA; Bloom SR
    Int J Obes (Lond); 2010 Dec; 34(12):1715-25. PubMed ID: 20531351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unraveling oxyntomodulin, GLP1's enigmatic brother.
    Pocai A
    J Endocrinol; 2012 Dec; 215(3):335-46. PubMed ID: 23019069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon-like peptide-1 inhibits insulinotropic effects of oxyntomodulin and glucagon in cattle.
    ThanThan S; Saito T; Yannaing S; Zhao H; Nakashima K; Kuwayama H
    Domest Anim Endocrinol; 2012 Apr; 42(3):155-64. PubMed ID: 22154917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.
    Shankar SS; Shankar RR; Mixson LA; Miller DL; Pramanik B; O'Dowd AK; Williams DM; Frederick CB; Beals CR; Stoch SA; Steinberg HO; Kelley DE
    Diabetes; 2018 Jun; 67(6):1105-1112. PubMed ID: 29545266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypothalamic injection of oxyntomodulin suppresses circulating ghrelin-like immunoreactivity.
    Patterson M; Murphy KG; Patel SR; Patel NA; Greenwood HC; Cooke JH; Campbell D; Bewick GA; Ghatei MA; Bloom SR
    Endocrinology; 2009 Aug; 150(8):3513-20. PubMed ID: 19359390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake.
    Ouberai MM; Gomes Dos Santos AL; Kinna S; Hornigold DC; Baker D; Naylor J; Liang L; Corkill DJ; Welland ME
    Front Endocrinol (Lausanne); 2023; 14():1217021. PubMed ID: 37554763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The mechanism of action for oxyntomodulin in the regulation of obesity.
    Wynne K; Field BC; Bloom SR
    Curr Opin Investig Drugs; 2010 Oct; 11(10):1151-7. PubMed ID: 20872318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin.
    Willard FS; Wootten D; Showalter AD; Savage EE; Ficorilli J; Farb TB; Bokvist K; Alsina-Fernandez J; Furness SG; Christopoulos A; Sexton PM; Sloop KW
    Mol Pharmacol; 2012 Dec; 82(6):1066-73. PubMed ID: 22930710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity.
    Bianchi E; Carrington PE; Ingallinella P; Finotto M; Santoprete A; Petrov A; Eiermann G; Kosinski J; Marsh DJ; Pocai A; SinhaRoy R; Pessi A
    Bioorg Med Chem; 2013 Nov; 21(22):7064-73. PubMed ID: 24094437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs.
    Druce MR; Minnion JS; Field BC; Patel SR; Shillito JC; Tilby M; Beale KE; Murphy KG; Ghatei MA; Bloom SR
    Endocrinology; 2009 Apr; 150(4):1712-22. PubMed ID: 19074579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line.
    Gros L; Thorens B; Bataille D; Kervran A
    Endocrinology; 1993 Aug; 133(2):631-8. PubMed ID: 8102095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle.
    ThanThan S; Asada Y; Saito T; Ochiiwa K; Zhao H; Yannaing S; Kuwayama H
    Domest Anim Endocrinol; 2013 Feb; 44(2):70-80. PubMed ID: 23122871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle.
    ThanThan S; Asada Y; Saito T; Ochiiwa K; Zhao H; Naing SW; Kuwayama H
    Domest Anim Endocrinol; 2017 Apr; 59():30-36. PubMed ID: 27888738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s).
    Jorgensen R; Kubale V; Vrecl M; Schwartz TW; Elling CE
    J Pharmacol Exp Ther; 2007 Jul; 322(1):148-54. PubMed ID: 17395766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. (D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions.
    Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2010 Dec; 80(11):1727-35. PubMed ID: 20735990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
    Claus TH; Pan CQ; Buxton JM; Yang L; Reynolds JC; Barucci N; Burns M; Ortiz AA; Roczniak S; Livingston JN; Clairmont KB; Whelan JP
    J Endocrinol; 2007 Feb; 192(2):371-80. PubMed ID: 17283237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.